Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099347 | 0.87 | GSK3B (0.50) | GSK3BMKNK1MKNK2PIK3CAPIK3CB | |
| SCHEMBL5093386 | 0.85 | MKNK1 (0.53) | GSK3BMKNK1MKNK2PIK3CAPIK3CB | |
| SCHEMBL5100332 | 0.84 | MMP2 (0.54) | GSK3BMKNK1MKNK2MEN1KMT2A | |
| SCHEMBL7855524 | 0.83 | MKNK1 (0.54) | GSK3BMKNK1MKNK2PIK3CAPIK3CB | |
| SCHEMBL5095126 | 0.82 | MKNK1 (0.51) | GSK3BMKNK1MKNK2PIK3CAPIK3CB | |
| SCHEMBL27570900 | 0.82 | GSK3B (0.60) | GSK3BMKNK1MKNK2CCNB2CDK1 | |
| SCHEMBL5091600 | 0.82 | GSK3B (0.53) | GSK3BMKNK1MKNK2CCNB2CDK1 | |
| SCHEMBL5089535 | 0.81 | MKNK1 (0.50) | GSK3BMKNK1MKNK2PIK3CAPIK3CB | |
| SCHEMBL5089385 | 0.81 | NAMPT (0.44) | GSK3BMKNK1MKNK2POLB | |
| SCHEMBL7143772 | 0.80 | GSK3B (0.41) | GSK3BMKNK1MKNK2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074886-A1 | GSK-3 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2009-03-19 | — | — | US | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1490093-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-20050054663-A1 | Bone disorders; osteoporosis | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1490093-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | CHIRON CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1087963-B1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003074072-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIA | CHIRON CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054663-A1 | Bone disorders; osteoporosis | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MKNK1 341/4885MKNK2 491/4885 |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | GSK3B 1/4885MKNK1 150/4885MKNK2 358/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | GSK3B 1/4885MKNK1 142/4885MKNK2 345/4885 |
| US-20090074886-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MKNK1 198/4885MKNK2 299/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | GSK3B 1/4885MKNK1 142/4885MKNK2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.